Anrukinzumab

Anrukinzumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	IL13
Clinical data
ATC code	none
Identifiers
CAS Number	910649-32-0^N
ChemSpider	none
UNII	OU46IGC49F
Chemical and physical data
Formula	C₆₄₅₂H₉₉₅₄N₁₇₁₄O₂₀₂₄S₄₆
Molar mass	145.4 kg/mol
^NY (what is this?) (verify)

Anrukinzumab (IMA-638^[1]) is a humanized monoclonal antibody designed for the treatment of asthma.^[2]

Anrukinzumab was developed by Wyeth.

References

↑ "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. Retrieved November 19, 2008.
↑ Statement On A Nonproprietary Name Adopted By The USAN Council: Anrukinzumab, American Medical Association.

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	Immunosuppression: Abrilumab Adalimumab Anifrolumab^† Atorolimumab Avelumab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab^† Fresolimumab Gimsilumab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Otilimab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab^† Ulocuplumab Varlilumab Immune activation: Ipilimumab Atezolizumab Durvalumab Nivolumab Pembrolizumab Tremelimumab^† Urelumab Other: Bertilimumab Zanolimumab
Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric ("-lixi-")	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized ("-lizu-")	Immunosuppressive: Aselizumab Apolizumab^§ Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab^† Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Inebilizumab^† Itolizumab Lampalizumab^† Letolizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab^† Reslizumab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab^† Siplizumab Spartalizumab^† Talizumab Teplizumab Tibulizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Non-immunosuppressive: Ibalizumab
Chimeric + humanized ("-lixizu-")	Otelixizumab Sutimlimab^† Tavolimab
Veterinary ("-lvet-")	Gilvetmab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab^† Ustekinumab
Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Bimekizumab^† Clazakizumab Enokizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab^† Tildrakizumab
Veterinary ("-kivet-")	Lokivetmab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Interleukin receptor modulators

Agonists: Interleukin 1 (α, β)
Mobenakin
Pifonakin

Antagonists: AF-12198
Anakinra
IL-1RA
Isunakinra

Antibodies: Canakinumab
Gevokizumab
Lutikizumab

Decoy receptors: Rilonacept (IL-1 Trap)

Agonists: Adargileukin alfa
Aldesleukin
Celmoleukin
Denileukin diftitox
Interleukin 2
Pegaldesleukin
Teceleukin
Tucotuzumab celmoleukin

Agonists: Daniplestim
Interleukin 3
Leridistim
Milodistim
Muplestim
Promegapoietin

Agonists: Binetrakin
Interleukin 4
Interleukin 13

Antagonists: Pitrakinra

Antibodies: Dupilumab
Pascolizumab

Agonists: Interleukin 5

Antagonists: YM-90709

Antisense oligonucleotides: TPI ASM8

Agonists: Atexakin alfa
Interleukin 6

Agonists: Interleukin 7

See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ) here instead.

Agonists: Interleukin 9

Antibodies: Enokizumab

Agonists: Ilodecakin
Interleukin 10 (CSIF)

Agonists: Interleukin 11 (AGIF)
Oprelvekin

Agonists: Edodekin alfa
Interleukin 12

Antibodies: Briakinumab
Ustekinumab

Agonists: Binetrakin
Cintredekin besudotox
Interleukin 4
Interleukin 13

Agonists: ALT-803
Interleukin 15

Agonists: Interleukin 17 (A, B, C, D, E (interleukin 25), F)

Antibodies: Brodalumab
Ixekizumab
Perakizumab
Remtolumab
Secukinumab
Vunakizumab

Agonists: Iboctadekin
Interleukin 18
Interleukin 37
Tadekinig

Binding proteins: IL18BP

Antibodies: Fletikumab (against IL-20)

Agonists: Denenicokin
Interleukin 21

Antibodies: NNC0114-0005
NNC0114-0006

Agonists: Interleukin 22

Antibodies: Fezakinumab (against IL-22)

Agonists: Interleukin 23 (SGRF)

Agonists: Interleukin 27 (interleukin 30)

Agonists: Interferon λ4 (IFN-λ4)
Interleukin 28 (A (IFN-λ2), B (IFN-λ3))
Interleukin-29 (IFN-λ1)

Agonists: Interleukin 31

Agonists: Interleukin 33

Agonists: Interleukin 36 (α, β, γ)
Interleukin 38

Antagonists: IL-36RA

Others

JAK	See here instead.
Others	Interleukin 14 (taxilin alpha, HMW-BCGF) Interleukin 16 (signals through CD4) Interleukin 24 (signals through IL-22Rα1/IL-20Rβ heterodimer) Interleukin 26 (signals through IL-20Rα/IL-10Rβ heterodimer) Interleukin 32 Interleukin 34 (signals through M-CSFR/CSF1R) Interleukin 35 Unsorted: Efavaleukin alfa Efineptakin alfa

See also: Receptor/signaling modulators; Signaling peptide/protein receptor modulators; Cytokine receptor modulators

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.